| Species |
Human |
| Protein Construction |
NPR1/NPRA (Gly33-Glu473)_x000D_
Accession # NP_000897.3 |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NPR1/NPRA mFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind AntiNPR1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
74.56 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NPR1 (natriuretic peptide receptor 1), a receptor of ANP (atrial natriuretic peptide) whitch acting through NPR1, provokes hypotension. NPR1 was abundantly expressed in endothelial cells and smooth muscle cells of small arteries and arterioles. NPR1 plays a crucial role in ANP-mediated blood pressure regulation, presumably by a mechanism that is RGS2-dependent in the acute phase and RGS2-independent in the chronic phase. |
| Synonyms |
ANP-A; ANPR-A; NPR-A; GC-A; ANPRA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
